

Contents

| | |
|--|-------------|
| Preface to the First Edition | xv |
| Preface to the Second Edition | xvii |
| Acknowledgements | xix |
| Abbreviations | xxi |
| 1 An introduction to drugs, their action and discovery | 1 |
| 1.1 Introduction | 1 |
| 1.2 What are drugs and why do we need new ones? | 1 |
| 1.3 Drug discovery and design: a historical outline | 3 |
| 1.3.1 The general stages in modern-day drug discovery and design | 7 |
| 1.4 Leads and analogues: some desirable properties | 9 |
| 1.4.1 Bioavailability | 9 |
| 1.4.2 Solubility | 10 |
| 1.4.3 Structure | 10 |
| 1.4.4 Stability | 11 |
| 1.5 Sources of leads and drugs | 14 |
| 1.5.1 Ethnopharmaceutical sources | 15 |
| 1.5.2 Plant sources | 15 |
| 1.5.3 Marine sources | 17 |
| 1.5.4 Microorganisms | 18 |
| 1.5.5 Animal sources | 20 |
| 1.5.6 Compound collections, data bases and synthesis | 20 |
| 1.5.7 The pathology of the diseased state | 21 |
| 1.5.8 Market forces and 'me-too drugs' | 21 |
| 1.6 Methods and routes of administration: the pharmaceutical phase | 21 |
| 1.7 Introduction to drug action | 24 |
| 1.7.1 The pharmacokinetic phase (ADME) | 25 |
| 1.7.2 The pharmacodynamic phase | 32 |
| 1.8 Classification of drugs | 33 |
| 1.8.1 Chemical structure | 33 |
| 1.8.2 Pharmacological action | 34 |
| 1.8.3 Physiological classification | 34 |
| 1.8.4 Prodrugs | 35 |
| 1.9 Questions | 35 |

| | | |
|----------|--|-----------|
| 2 | Drug structure and solubility | 37 |
| 2.1 | Introduction | 37 |
| 2.2 | Structure | 37 |
| 2.3 | Stereochemistry and drug design | 38 |
| 2.3.1 | Structurally rigid groups | 38 |
| 2.3.2 | Conformation | 39 |
| 2.3.3 | Configuration | 41 |
| 2.4 | Solubility | 44 |
| 2.4.1 | Solubility and the physical nature of the solute | 44 |
| 2.5 | Solutions | 46 |
| 2.6 | The importance of water solubility | 47 |
| 2.7 | Solubility and the structure of the solute | 49 |
| 2.8 | Salt formation | 50 |
| 2.9 | The incorporation of water solubilising groups in a structure | 52 |
| 2.9.1 | The type of group | 52 |
| 2.9.2 | Reversible and irreversible groups | 53 |
| 2.9.3 | The position of the water solubilising group | 53 |
| 2.9.4 | Methods of introduction | 54 |
| 2.9.5 | Improving lipid solubility | 59 |
| 2.10 | Formulation methods of improving water solubility | 59 |
| 2.10.1 | Cosolvents | 59 |
| 2.10.2 | Colloidal solutions | 59 |
| 2.10.3 | Emulsions | 60 |
| 2.11 | The effect of pH on the solubility of acidic and basic drugs | 61 |
| 2.12 | Partition | 63 |
| 2.12.1 | Practical determination of partition coefficients | 65 |
| 2.12.2 | Theoretical determination of partition coefficients | 66 |
| 2.13 | Surfactants and amphiphiles | 66 |
| 2.13.1 | Drug solubilisation | 69 |
| 2.13.2 | Mixed micelles as drug delivery systems | 71 |
| 2.13.3 | Vesicles and liposomes | 72 |
| 2.14 | Questions | 72 |
| 3 | Structure–activity and quantitative structure relationships | 75 |
| 3.1 | Introduction | 75 |
| 3.2 | Structure–activity relationship (SAR) | 76 |
| 3.3 | Changing size and shape | 77 |
| 3.3.1 | Changing the number of methylene groups in chains and rings | 77 |
| 3.3.2 | Changing the degree of unsaturation | 78 |
| 3.3.3 | Introduction or removal of a ring system | 78 |
| 3.4 | Introduction of new substituents | 80 |
| 3.4.1 | Methyl groups | 81 |
| 3.4.2 | Halogen groups | 83 |
| 3.4.3 | Hydroxy groups | 84 |
| 3.4.4 | Basic groups | 84 |
| 3.4.5 | Carboxylic and sulphonic acid groups | 85 |
| 3.4.6 | Thiols, sulphides and other sulphur groups | 85 |
| 3.5 | Changing the existing substituents of a lead | 86 |
| 3.6 | Case study: a SAR investigation to discover potent geminal bisphosphonates | 87 |
| 3.7 | Quantitative structure–activity relationship (QSAR) | 90 |
| 3.7.1 | Regression analysis | 93 |
| 3.7.2 | The lipophilic parameters | 94 |

| | | |
|----------|---|------------|
| 3.7.3 | Electronic parameters | 99 |
| 3.7.4 | Steric parameters | 102 |
| 3.8 | Questions | 110 |
| 4 | Computer-aided drug design | 113 |
| 4.1 | Introduction | 113 |
| 4.1.1 | Models | 114 |
| 4.1.2 | Molecular modelling methods | 115 |
| 4.1.3 | Computer graphics | 116 |
| 4.2 | Molecular mechanics | 117 |
| 4.2.1 | Creating a molecular model using molecular mechanics | 120 |
| 4.3 | Molecular dynamics | 123 |
| 4.3.1 | Conformational analysis | 124 |
| 4.4 | Quantum mechanics | 124 |
| 4.5 | Docking | 127 |
| 4.5.1 | <i>De novo</i> design | 128 |
| 4.6 | Comparing three-dimensional structures by the use of overlays | 130 |
| 4.6.1 | An example of the use of overlays | 132 |
| 4.7 | Pharmacophores and some of their uses | 133 |
| 4.7.1 | High-resolution X-ray crystallography or NMR | 133 |
| 4.7.2 | Analysis of the structures of different ligands | 134 |
| 4.8 | Modelling protein structures | 135 |
| 4.9 | Three-dimensional QSAR | 136 |
| 4.9.1 | Advantages and disadvantages | 140 |
| 4.10 | Other uses of computers in drug discovery | 141 |
| 4.11 | Questions | 143 |
| 5 | Combinatorial chemistry | 145 |
| 5.1 | Introduction | 145 |
| 5.1.1 | The design of combinatorial syntheses | 147 |
| 5.1.2 | The general techniques used in combinatorial synthesis | 148 |
| 5.2 | The solid support method | 148 |
| 5.2.1 | General methods in solid support combinatorial chemistry | 150 |
| 5.2.2 | Parallel synthesis | 152 |
| 5.2.3 | Furka's mix and split technique | 155 |
| 5.3 | Encoding methods | 157 |
| 5.3.1 | Sequential chemical tagging | 157 |
| 5.3.2 | Still's binary code tag system | 160 |
| 5.3.3 | Computerised tagging | 161 |
| 5.4 | Combinatorial synthesis in solution | 161 |
| 5.4.1 | Parallel synthesis in solution | 162 |
| 5.4.2 | The formation of libraries of mixtures | 163 |
| 5.4.3 | Libraries formed using monomethyl polyethylene glycol (OMe-PEG) | 164 |
| 5.4.4 | Libraries produced using dendrimers as soluble supports | 164 |
| 5.4.5 | Libraries formed using fluorocarbon reagents | 165 |
| 5.4.6 | Libraries produced using resin-bound scavenging agents | 166 |
| 5.4.7 | Libraries produced using resin-bound reagents | 168 |
| 5.4.8 | Resin capture of products | 168 |
| 5.5 | Deconvolution | 169 |
| 5.6 | High-throughput screening (HTS) | 170 |
| 5.6.1 | Biochemical assays | 171 |
| 5.6.2 | Whole cell assays | 173 |
| 5.6.3 | Hits and hit rates | 173 |

| | | |
|----------|--|------------|
| 5.7 | Automatic methods of library generation and analysis | 174 |
| 5.8 | Questions | 175 |
| 6 | Drugs from natural sources | 177 |
| 6.1 | Introduction | 177 |
| 6.2 | Bioassays | 179 |
| 6.2.1 | Screening tests | 180 |
| 6.2.2 | Monitoring tests | 183 |
| 6.3 | Dereplication | 185 |
| 6.4 | Structural analysis of the isolated substance | 186 |
| 6.5 | Active compound development | 188 |
| 6.6 | Extraction procedures | 189 |
| 6.6.1 | General considerations | 190 |
| 6.6.2 | Commonly used methods of extraction | 191 |
| 6.6.3 | Cleaning up procedures | 195 |
| 6.7 | Fractionation methods | 195 |
| 6.7.1 | Liquid-liquid partition | 196 |
| 6.7.2 | Chromatographic methods | 199 |
| 6.7.3 | Precipitation | 200 |
| 6.7.4 | Distillation | 200 |
| 6.7.5 | Dialysis | 202 |
| 6.7.6 | Electrophoresis | 202 |
| 6.8 | Case history: the story of Taxol | 202 |
| 6.9 | Questions | 206 |
| 7 | Biological membranes | 207 |
| 7.1 | Introduction | 207 |
| 7.2 | The plasma membrane | 208 |
| 7.2.1 | Lipid components | 209 |
| 7.2.2 | Protein components | 211 |
| 7.2.3 | The carbohydrate component | 213 |
| 7.2.4 | Similarities and differences between plasma membranes in different cells | 213 |
| 7.2.5 | Cell walls | 214 |
| 7.2.6 | Bacterial cell exterior surfaces | 217 |
| 7.2.7 | Animal cell exterior surfaces | 218 |
| 7.2.8 | Virus | 218 |
| 7.2.9 | Tissue | 219 |
| 7.2.10 | Human skin | 219 |
| 7.3 | The transfer of species through cell membranes | 220 |
| 7.3.1 | Osmosis | 220 |
| 7.3.2 | Filtration | 221 |
| 7.3.3 | Passive diffusion | 221 |
| 7.3.4 | Facilitated diffusion | 223 |
| 7.3.5 | Active transport | 223 |
| 7.3.6 | Endocytosis | 224 |
| 7.3.7 | Exocytosis | 225 |
| 7.4 | Drug action that affects the structure of cell membranes and walls | 225 |
| 7.4.1 | Antifungal agents | 226 |
| 7.4.2 | Antibacterial agents (antibiotics) | 230 |
| 7.4.3 | Local anaesthetics | 244 |
| 7.5 | Questions | 249 |

| | | |
|----------|--|------------|
| 8 | Receptors and messengers | 251 |
| 8.1 | Introduction | 251 |
| 8.2 | The chemical nature of the binding of ligands to receptors | 252 |
| 8.3 | Structure and classification of receptors | 254 |
| 8.4 | General mode of operation | 256 |
| 8.4.1 | Superfamily Type 1 | 259 |
| 8.4.2 | Superfamily Type 2 | 260 |
| 8.4.3 | Superfamily Type 3 | 263 |
| 8.4.4 | Superfamily Type 4 | 264 |
| 8.5 | Ligand–response relationships | 265 |
| 8.5.1 | Experimental determination of ligand concentration–response curves | 266 |
| 8.5.2 | Agonist concentration–response relationships | 267 |
| 8.5.3 | Antagonist concentration–receptor relationships | 268 |
| 8.5.4 | Partial agonists | 271 |
| 8.5.5 | Desensitisation | 272 |
| 8.6 | Ligand–receptor theories | 272 |
| 8.6.1 | Clark’s occupancy theory | 272 |
| 8.6.2 | The rate theory | 277 |
| 8.6.3 | The two-state model | 278 |
| 8.7 | Drug action and design | 279 |
| 8.7.1 | Agonists | 279 |
| 8.7.2 | Antagonists | 281 |
| 8.7.3 | Citalopram, an antagonist antidepressant discovered by a rational approach | 282 |
| 8.7.4 | β -Blockers | 285 |
| 8.8 | Questions | 289 |
| | | |
| 9 | Enzymes | 291 |
| 9.1 | Introduction | 291 |
| 9.2 | Classification and nomenclature | 293 |
| 9.3 | Active sites and catalytic action | 295 |
| 9.3.1 | Allosteric activation | 297 |
| 9.4 | Regulation of enzyme activity | 298 |
| 9.4.1 | Covalent modification | 298 |
| 9.4.2 | Allosteric control | 298 |
| 9.4.3 | Proenzyme control | 300 |
| 9.5 | The specific nature of enzyme action | 300 |
| 9.6 | The mechanisms of enzyme action | 302 |
| 9.7 | The general physical factors affecting enzyme action | 302 |
| 9.8 | Enzyme kinetics | 303 |
| 9.8.1 | Single substrate reactions | 303 |
| 9.8.2 | Multiple substrate reactions | 305 |
| 9.9 | Enzyme inhibitors | 306 |
| 9.9.1 | Reversible inhibitors | 307 |
| 9.9.2 | Irreversible inhibition | 312 |
| 9.10 | Transition state inhibitors | 318 |
| 9.11 | Enzymes and drug design: some general considerations | 320 |
| 9.12 | Examples of drugs used as enzyme inhibitors | 321 |
| 9.12.1 | Sulphonamides | 321 |
| 9.12.2 | Captopril and related drugs | 323 |
| 9.12.3 | Statins | 326 |
| 9.13 | Enzymes and drug resistance | 329 |
| 9.13.1 | Changes in enzyme concentration | 330 |

| | | |
|-----------|--|------------|
| 9.13.2 | An increase in the production of the substrate | 331 |
| 9.13.3 | Changes in the structure of the enzyme | 331 |
| 9.13.4 | The use of an alternative metabolic pathway | 332 |
| 9.14 | Ribozymes | 332 |
| 9.15 | Questions | 332 |
| 10 | Nucleic acids | 335 |
| 10.1 | Introduction | 335 |
| 10.2 | Deoxyribonucleic acid (DNA) | 336 |
| 10.2.1 | Structure | 337 |
| 10.3 | The general functions of DNA | 338 |
| 10.4 | Genes | 339 |
| 10.5 | Replication | 340 |
| 10.6 | Ribonucleic acid (RNA) | 341 |
| 10.7 | Messenger RNA (mRNA) | 342 |
| 10.8 | Transfer RNA (tRNA) | 343 |
| 10.9 | Ribosomal RNA (rRNA) | 345 |
| 10.10 | Protein synthesis | 345 |
| 10.10.1 | Activation | 345 |
| 10.10.2 | Initiation | 346 |
| 10.10.3 | Elongation | 347 |
| 10.10.4 | Termination | 348 |
| 10.11 | Protein synthesis in prokaryotic and eukaryotic cells | 348 |
| 10.11.1 | Prokaryotic cells | 348 |
| 10.11.2 | Eukaryotic cells | 350 |
| 10.12 | Bacterial protein synthesis inhibitors (antimicrobials) | 350 |
| 10.12.1 | Aminoglycosides | 351 |
| 10.12.2 | Chloramphenicol | 355 |
| 10.12.3 | Tetracyclines | 356 |
| 10.12.4 | Macrolides | 359 |
| 10.12.5 | Lincomycins | 360 |
| 10.13 | Drugs that target nucleic acids | 362 |
| 10.13.1 | Antimetabolites | 362 |
| 10.13.2 | Enzyme inhibitors | 368 |
| 10.13.3 | Intercalating agents | 372 |
| 10.13.4 | Alkylating agents | 374 |
| 10.13.5 | Antisense drugs | 377 |
| 10.13.6 | Chain cleaving agents | 379 |
| 10.14 | Viruses | 380 |
| 10.14.1 | Structure and replication | 380 |
| 10.14.2 | Classification | 381 |
| 10.14.3 | Viral diseases | 383 |
| 10.14.4 | Antiviral drugs | 384 |
| 10.15 | Recombinant DNA technology (genetic engineering) | 389 |
| 10.15.1 | Gene cloning | 389 |
| 10.15.2 | Medical applications | 392 |
| 10.16 | Questions | 401 |
| 11 | Pharmacokinetics | 403 |
| 11.1 | Introduction | 403 |
| 11.1.1 | General classification of pharmacokinetic properties | 405 |
| 11.1.2 | Drug regimens | 405 |
| 11.1.3 | The importance of pharmacokinetics in drug discovery | 406 |
| 11.2 | Drug concentration analysis and its therapeutic significance | 407 |

| | | |
|-----------|---|------------|
| 11.3 | Pharmacokinetic models | 409 |
| 11.4 | Intravascular administration | 411 |
| 11.4.1 | Distribution | 412 |
| 11.5 | Extravascular administration | 425 |
| 11.5.1 | Dissolution | 428 |
| 11.5.2 | Absorption | 429 |
| 11.5.3 | Single oral dose | 430 |
| 11.5.4 | The calculation of t_{\max} and C_{\max} | 433 |
| 11.5.5 | Repeated oral doses | 434 |
| 11.6 | The use of pharmacokinetics in drug design | 435 |
| 11.7 | Extrapolation of animal experiments to humans | 435 |
| 11.8 | Questions | 436 |
| 12 | Drug metabolism | 439 |
| 12.1 | Introduction | 439 |
| 12.1.1 | The stereochemistry of drug metabolism | 439 |
| 12.1.2 | Biological factors affecting metabolism | 440 |
| 12.1.3 | Environmental factors affecting metabolism | 443 |
| 12.1.4 | Species and metabolism | 443 |
| 12.1.5 | Enzymes and metabolism | 443 |
| 12.2 | Secondary pharmacological implications of metabolism | 443 |
| 12.2.1 | Inactive metabolites | 444 |
| 12.2.2 | Metabolites with a similar activity to the drug | 444 |
| 12.2.3 | Metabolites with a dissimilar activity to the drug | 444 |
| 12.2.4 | Toxic metabolites | 445 |
| 12.3 | Sites of action | 445 |
| 12.4 | Phase I metabolic reactions | 446 |
| 12.4.1 | Oxidation | 446 |
| 12.4.2 | Reduction | 448 |
| 12.4.3 | Hydrolysis | 448 |
| 12.4.4 | Hydration | 449 |
| 12.4.5 | Other Phase I reactions | 449 |
| 12.5 | Examples of Phase I metabolic reactions | 449 |
| 12.6 | Phase II metabolic routes | 454 |
| 12.7 | Pharmacokinetics of metabolites | 457 |
| 12.8 | Drug metabolism and drug design | 458 |
| 12.9 | Prodrugs | 460 |
| 12.9.1 | Bioprecursor prodrugs | 461 |
| 12.9.2 | Carrier prodrugs | 462 |
| 12.9.3 | Photoactivated prodrugs | 464 |
| 12.9.4 | The design of carrier prodrug systems for specific purposes | 465 |
| 12.10 | Questions | 475 |
| 13 | Complexes and chelating agents | 477 |
| 13.1 | Introduction | 477 |
| 13.2 | The shapes and structures of complexes | 478 |
| 13.2.1 | Ligands | 479 |
| 13.2.2 | Bridging ligands | 483 |
| 13.2.3 | Metal-metal bonds | 483 |
| 13.2.4 | Metal clusters | 483 |
| 13.3 | Metal-ligand affinities | 485 |
| 13.3.1 | Affinity and equilibrium constants | 485 |
| 13.3.2 | Hard and soft acids and bases | 487 |

| | | |
|-----------|--|------------|
| 13.3.3 | The general medical significance of complex stability | 488 |
| 13.4 | The general roles of metal complexes in biological processes | 488 |
| 13.5 | Therapeutic uses | 491 |
| 13.5.1 | Metal poisoning | 491 |
| 13.5.2 | Anticancer agents | 494 |
| 13.5.3 | Antiarthritics | 497 |
| 13.5.4 | Antimicrobial complexes | 498 |
| 13.5.5 | Photoactivated metal complexes | 499 |
| 13.6 | Drug action and metal chelation | 501 |
| 13.7 | Questions | 501 |
| 14 | Nitric oxide | 503 |
| 14.1 | Introduction | 503 |
| 14.2 | The structure of nitric oxide | 503 |
| 14.3 | The chemical properties of nitric oxide | 504 |
| 14.3.1 | Oxidation | 505 |
| 14.3.2 | Salt formation | 506 |
| 14.3.3 | Reaction as an electrophile | 507 |
| 14.3.4 | Reaction as an oxidising agent | 507 |
| 14.3.5 | Complex formation | 508 |
| 14.3.6 | Nitric oxide complexes with iron | 508 |
| 14.3.7 | The chemical properties of nitric oxide complexes | 510 |
| 14.3.8 | The chemistry of related compounds | 512 |
| 14.4 | The cellular production and role of nitric oxide | 514 |
| 14.4.1 | General mode of action | 516 |
| 14.4.2 | Suitability of nitric oxide as a chemical messenger | 518 |
| 14.4.3 | Metabolism | 518 |
| 14.5 | The role of nitric oxide in physiological and pathophysiological states | 519 |
| 14.5.1 | The role of nitric oxide in the cardiovascular system | 519 |
| 14.5.2 | The role of nitric oxide in the nervous system | 520 |
| 14.5.3 | Nitric oxide and diabetes | 522 |
| 14.5.4 | Nitric oxide and impotence | 522 |
| 14.5.5 | Nitric oxide and the immune system | 523 |
| 14.6 | Therapeutic possibilities | 524 |
| 14.6.1 | Compounds that reduce nitric oxide generation | 524 |
| 14.6.2 | Compounds that supply nitric oxide | 526 |
| 14.6.3 | The genetic approach | 529 |
| 14.7 | Questions | 529 |
| 15 | An introduction to drug and analogue synthesis | 531 |
| 15.1 | Introduction | 531 |
| 15.2 | Some general considerations | 532 |
| 15.2.1 | Starting materials | 532 |
| 15.2.2 | Practical considerations | 532 |
| 15.2.3 | The overall design | 532 |
| 15.2.4 | The use of protecting groups | 533 |
| 15.3 | Asymmetry in syntheses | 534 |
| 15.3.1 | The use of non-stereoselective reactions to produce stereospecific centres | 535 |
| 15.3.2 | The use of stereoselective reactions to produce stereogenic centres | 535 |
| 15.3.3 | General methods of asymmetric synthesis | 541 |
| 15.3.4 | Methods of assessing the purity of stereoisomers | 547 |
| 15.4 | Designing organic syntheses | 548 |
| 15.4.1 | An introduction to the disconnection approach | 548 |

| | | |
|-----------|--|------------|
| 15.4.2 | Convergent synthesis | 554 |
| 15.5 | Partial organic synthesis of xenobiotics | 556 |
| 15.6 | Questions | 557 |
| 16 | Drug development and production | 559 |
| 16.1 | Introduction | 559 |
| 16.2 | Chemical development | 560 |
| 16.2.1 | Chemical engineering issues | 561 |
| 16.2.2 | Chemical plant: health and safety considerations | 562 |
| 16.2.3 | Synthesis quality control | 563 |
| 16.2.4 | A case study | 563 |
| 16.3 | Pharmacological and toxicological testing | 565 |
| 16.4 | Drug metabolism and pharmacokinetics | 569 |
| 16.5 | Formulation development | 570 |
| 16.6 | Production and quality control | 570 |
| 16.7 | Patent protection | 571 |
| 16.8 | Regulation | 572 |
| 16.9 | Questions | 573 |
| | Selected further reading | 575 |
| | Answers to questions | 579 |
| | Index | 601 |